Femlyv is a drug owned by Millicent Puerto Rico Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 24, 2041. Details of Femlyv's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12178824 | Orodispersible formulations |
Jun, 2041
(16 years from now) | Active |
FDA has granted several exclusivities to Femlyv. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Femlyv, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Femlyv.
Exclusivity Information
Femlyv holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Femlyv's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2027 |
US patents provide insights into the exclusivity only within the United States, but Femlyv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Femlyv's family patents as well as insights into ongoing legal events on those patents.
Femlyv's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Femlyv's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 24, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Femlyv Generic API suppliers:
Ethinyl Estradiol; Norethindrone Acetate is the generic name for the brand Femlyv. 15 different companies have already filed for the generic of Femlyv, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Femlyv's generic
Alternative Brands for Femlyv
There are several other brand drugs using the same active ingredient (Ethinyl Estradiol; Norethindrone Acetate) as Femlyv. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| Apil |
| ||||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone Acetate, Femlyv's active ingredient. Check the complete list of approved generic manufacturers for Femlyv
About Femlyv
Femlyv is a drug owned by Millicent Puerto Rico Llc. Femlyv uses Ethinyl Estradiol; Norethindrone Acetate as an active ingredient. Femlyv was launched by Millicent Pr in 2024.
Approval Date:
Femlyv was approved by FDA for market use on 22 July, 2024.
Active Ingredient:
Femlyv uses Ethinyl Estradiol; Norethindrone Acetate as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone Acetate ingredient
Dosage:
Femlyv is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.02MG;1MG | TABLET, ORALLY DISINTEGRATING | Prescription | ORAL |